RCP
BIIB icon

Rothschild Capital Partners’s Biogen BIIB Stock Holding History

Rothschild Capital Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-500
Closed -$153K – 68
2015
Q4 		$153K Sell
500
-1,000
-67% -$287K 0.08% 41
2015
Q3 		$438K Buy
1,500
+500
+50% +$165K 0.23% 33
2015
Q2 		$404K Buy
+1,000
New +$401K 0.17% 36

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rothschild Capital Partners's BIIB Position: Q1 2016 in Review

Rothschild Capital Partners sold out of Biogen (BIIB) in Q1 2016, closing a stake of 1,150 shares — an estimated $352K sold.

Rothschild Capital Partners first reported a position in BIIB in Q4 2015 and held it in 1 quarter. The position peaked at $352K in Q4 2015. 948 funds tracked by Wall St. Rank hold BIIB as of Q1 2016.

  • Rothschild Capital Partners reported no remaining Biogen position as of Q1 2016 after selling out during the quarter.
  • Rothschild Capital Partners sold 1,150 Biogen shares in Q1 2016, an estimated $352K.
  • Rothschild Capital Partners first reported a position in Biogen in Q4 2015 and held it in 1 quarter.
  • Rothschild Capital Partners's Biogen position peaked at $352K in Q4 2015.
  • 948 funds tracked by Wall St. Rank held Biogen as of Q1 2016.

Based on Rothschild Capital Partners's 13F filing for Q1 2016, filed 4 May 2016.